|
|
Phase I COVID-19 Vaccines
This site presents COVID-19 vaccines that are currently in Phase I clinical trials as of February 17, 2021.
Existing vaccines in Phase I clinical trial include:
- AdCOVID
- Clinical trial ID:
- Phase I: NCT04679909
- Age subgroups: 18-55 years
- Location: USA
- Type: Recombinant vector vaccine
- Manufacturer: Altimmune, Inc.
- VIOLIN: 5835
- VO: VO_0005153
- AdimrSC-2f
- Clinical trial ID:
- Phase I: NCT04522089
- Age subgroups: 20-60 years
- Location: Taiwan
- Type: Subunit vaccine
- Manufacturer: Adimmune Corporation
- VO: VO_0005173
- ARCoV
- Clinical trial ID:
- Type: mRNA vaccine
- Manufacturer: Academy of Military Sciences, Walvax Biotech.
- Publications:
- Zhang et al. A Thermostable mRNA Vaccine against COVID-19. Cell. 2020; 182(5); 1271-1283. [PubMed: 32795413].
- VIOLIN: 5783
- VO: VO_0005161
- bacTRL-Spike
- Clinical trial ID:
- Phase I: NCT04334980
- Age subgroups: 18-59 years
- Location: Australia
- Type: DNA vaccine
- Manufacturer: Symvivo
- VIOLIN: 5817
- VO: VO_0005174
- ChulaCov19
- Clinical trial ID:
- Phase I: NCT04566276
- Age subgroups:
- Phase I: 18-55 years, 65-75 years
- Phase II: 18-55 years, 65-75 years
- Location: Australia
- Type: mRNA vaccine
- Manufacturer: Chulalongkorn University
- VIOLIN: 5818
- VO: VO_0005175
- COH04S1
- Clinical trial ID:
- Phase I: NCT04639466
- Age subgroups: 18-55 years
- Location: USA
- Type: Recombinant vector vaccine
- Manufacturer: City of Hope Medical Center
- Publications
- Chiuppesi et al. Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform. Nat Commun. 2020; 11(1); 6121. [PubMed: 33257686].
- VIOLIN: 5819
- VO: VO_0005176
- CORVax12
- Clinical trial ID:
- Phase I: NCT04627675
- Age subgroups: 18-50 years, 60 years and above
- Location: USA
- Type: DNA vaccine
- Manufacturer: Providence Health & Services, OncoSec Medical Inc.
- VIOLIN: 5820
- VO: VO_0005183
- COVID-19 aAPC vaccine
- Clinical trial ID:
- Phase I: NCT04299724
- Age subgroups: 6 months to 80 years
- Location: China
- Type: Recombinant vector vaccine
- Manufacturer: Shenzhen Geno-Immune Medical Institute
- VIOLIN: 5821
- VO: VO_0005184
- COVID-19 inactivated virus vaccine by Shifa Pharmed
- Clinical trial ID:
- Type: Inactivated or "killed" vaccine
- Manufacturer: Shifa Pharmed Industrial Co
- VIOLIN: 5815
- COVID-19 RNA vaccine by Shulan Hospital
- Clinical trial ID:
- Type: DNA vaccine
- Manufacturer: Shulan Hospital, Center for Disease Control and Prevention of Guangxi Zhuang Autonomous Region
- VIOLIN: 5822
- VO: VO_0005185
- Covigenix VAX-001
- Clinical trial ID:
- Phase I: NCT04591184
- Age subgroups: 18-54 years, 65-84 years
- Location: Canada
- Type: DNA vaccine
- Manufacturer: Entos Pharmaceuticals
- VIOLIN: 5823
- VO: VO_0005186
- COVI-VAC
- Clinical trial ID:
- Phase I: NCT04619628
- Age subgroups: 18-30 years
- Location: UK
- Type: Live, attenuated vaccine
- Manufacturer: Codagenix, Inc.
- VIOLIN: 5824
- VO: VO_0005187
- ERUCOV-VAC
- Clinical trial ID:
- Phase I: NCT04691947
- Age subgroups: 18-55 years
- Location: Turkey
- Type: Inactivated or "killed" vaccine
- Manufacturer: Erciyes University
- VIOLIN: 5836
- VO: VO_0005188
- GRAd-CoV2
- Clinical trial ID:
- Phase I: NCT04528641
- Age subgroups: 18-55 years, 65-85 years
- Location: Italy
- Type: Recombinant vector vaccine
- Manufacturer: ReiThera, Leukocare, Univercells
- VIOLIN: 5787
- VO: VO_0005169
- hAd5-COVID-19
- Clinical trial ID:
- Phase I: NCT04732468
- Age subgroups: 18-55 years
- Location: USA
- Phase I: NCT04591717
- Age subgroups: 18-55 years
- Location: USA
- Phase I: NCT04710303
- Age subgroups: 18-50 years
- Location: USA
- Type: Recombinant vector vaccine
- Manufacturer: ImmunityBio, Inc.; NantKwest Inc.
- VIOLIN: 5825
- VO: VO_0005189
- IMP CoVac-1
- Clinical trial ID:
- Phase I: NCT04546841
- Age subgroups: 18-55 years, 56-74 years, 75 years and above
- Location: Germany
- Type: Subunit vaccine
- Manufacturer: University Hospital Tuebingen
- VIOLIN: 5826
- VO: VO_0005190
- LNP-nCoVsaRNA
- Other names: COVAC1
- Clinical trial ID:
- Type: mRNA vaccine
- Manufacturer: Imperial College London, Morningside Ventures
- Publications:
- McKay et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat Commun. 2020; 11(1); 3523. [PubMed: 32647131].
- VIOLIN: 5771
- VO: VO_0005156
- MVA-SARS-2-S
- Clinical trial ID:
- Phase I: NCT04569383
- Age subgroups: 18-55 years
- Location: Germany
- Type: Recombinant vector vaccine
- Manufacturer: Universitätsklinikum Hamburg-Eppendorf, Ludwig-Maximilians - University of Munich
- VIOLIN: 5827
- VO: VO_0005191
- Razi Cov Pars
- Clinical trial ID:
- Type: Subunit vaccine
- Manufacturer: Razi Vaccine and Serum Research Institute
- VIOLIN: 5779
- Recombinant spike protein with Advax™ adjuvant
- Clinical trial ID:
- Phase I: NCT04453852
- Age subgroups: 18-65 years
- Location: Australia
- Type: Subunit vaccine
- Manufacturer: Vaxine, Medytox
- VIOLIN: 5829
- VO: VO_0005193
- VXA-CoV2-1
- Clinical trial ID:
- Phase I: NCT04563702
- Age subgroups: 18-54 years
- Location: USA
- Type: Recombinant vector vaccine
- Manufacturer: Vaxart
- VIOLIN: 5832
- VO: VO_0005196
Provenance: All data in Cov19VaxKB originates from manual curation of reliable resources.
Note: The page was updated on February 17, 2021. We plan to update this page on a weekly or even a daily basis. Please provide us with any new information that you believe would be useful if included on the website.
|
